Related news from
Mon, 14 Dec 2020 04:08:07 +0000	Is HTGC A Good Stock To Buy Now? The 800+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the third quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]
Wed, 25 Nov 2020 13:22:29 +0000	4 Big Dividends to Be Thankful For Big dividends. And I mean really big dividends. Yields that are multiples of the average of the members of the S&P 500 Index. But big dividends are worthless if the companies behind them aren’t up to sustaining them, or if the dividend stocks aren’t working in the market. A dividend yield won’t be worth much to anything on dividend stocks that are lagging or tanking. Investing for dividend income takes work researching companies — both their income statements and their balance sheets. As a former banker and bond guy — I have always been about balance sheets as just as important as income statements. Income statements cover the revenues from products and services, and investors get all excited about growth expectations. But for me, it also comes down to operating margins. Sales are great, but not if a company loses more than what they generate in revenue. And of course, problems will happen. So, I look at what will happen to either impact sales or costs. And in turn, I work through how the company has or will cope.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Balance sheets are crucial, as without credit, even the best product idea won’t make for a great company that’s headed into receivership. And earlier this year with the Covid-19 mess including lockdowns, the status of companies — including their operations, their suppliers and customers — was critical to analyze. But so, too, was the debt and credit of the companies, so that they could power through even the worst parts of the Biblical plagues that might be striking their core businesses. 10 Best Stocks to Buy for Investors Under 30 The following big dividend stocks have been vetted by me and I’ve been recommending them for some time. And that time includes both good and bad conditions — so the dividends are sustainable. AllianceBernstein (NYSE:AB) Compass Diversified (NYSE:CODI) Hercules Capital (NYSE:HTGC) Sixth Street Specialty Lending (NYSE:TSLX) Dividend Stocks: AllianceBernstein (AB) AllianceBernstein is an asset management company that is set up as a passthrough. This means that it avoids general corporate income taxes and dividends can come with some tax advantages. Asset managers are all about getting and keeping assets under management (AUM). AUM is what generates fee income — so the more they have, the more fee income they get. AUM keeps rising for AllianceBernstein, with the average for the trailing five years alone running at 6.51% on a compound annual growth rate (CAGR) basis. This fuels dependable revenue from fee income. And this fuels the dividend, which is yielding 8.58%. And over the same trailing five years — the dividend distributions have been hiked by an annual average of 7.96%. And it has great credit and fiscal management. Source: AllianceBernstein (AB) Total Return — Source: Bloomberg The stock isn’t just about the dividend, as the price has also reflected the growth in the value of the company. Over the past five years it has returned 95.8% for an annual equivalent of 14.37% which is above the return for the S&P 500 Index. Compass Diversified (CODI) Compass Diversified is an investment holding company under the Investment Company Act of 1940, and as such, it again avoids general corporate income taxes. It buys, owns and occasionally sells middle-market companies that are in strongly branded industrial and very-specialized consumer/professional products. One of the companies in the portfolio is Foam Fabricators which makes specialized foam for shipments of goods. And the company is part of the Covid-19 Warp Speed project as the provider for packaging for vaccines. 7 Upcoming IPOs to Watch Heading Into 2021 Revenue continues to flow, with gains that over the past five years has been climbing by an average of 16.89% annually (CAGR). And the company has lots of cash and very little debt. And the stock trades at a discount to trailing sales by 20%. Source: Compass Diversified (CODI) Total Return — Source: Bloomberg The stock performs with a return over the past five years of 83.78% for an annual equivalent of 12.93%. This means growth with that dividend. And the dividend yields a nice 7.32%. Hercules Capital (HTGC) Hercules Capita is a venture capital company set up as a business development company (BDC) under both the Investment Company Act of 1940 and the Small Business Investment Incentives Act of 1980. This means that it also avoids general corporate income taxes. It funds technology companies in various stages of development and works with them on development on their way to their exit strategies that might include a sale or initial public offering (IPO). And its track record has plenty of bold-faced named companies that are not titans of tech. Its portfolio generates high income from finance and equity gains from transactions. And the stock has returned 95.70% over the trailing five years for an annual equivalent of 14.35%. Source: Hercules Capital (HTGC) Total Return — Source: Bloomberg Controlled debt and huge net interest margins along with a phenomenal efficiency ratio for a financial (meaning that it costs a fraction to make each dollar of revenue) all work to make a compelling well-run company. The dividend yields 11.34% on an annual basis including regular special dividends. And those distributions keep rising over the years. Tech with income and growth makes Hercules one of the great dividend stocks right now. Sixth Street Specialty Lending (TSLX) Sixth Street Specialty Lending is another company set up as a BDC with the advantage of avoiding general corporate income taxes. It is very skilled at providing business and corporate financing to well-qualified companies in targeted businesses and markets. Like for Hercules, it has ample net interest margin (the difference between financial costs and revenue running at 9.9%. And it also is very efficient on costs with an efficiency ratio of 14.90% which means that it only costs 14.9 cents to make each dollar in revenue. Debts are low and well-managed making for good credit. And the stock performs not just with dividends but also with gains. It has returned 96.16% over the past five years alone for an annual equivalent of 14.41%. Source: Sixth Street Specialty Lending (TSLX) Total Return — Source: Bloomberg And the dividend yields an impressive annual rate of 10.88% including regular special dividend distributions. And with potential changes in traditional bank regulations over the coming years, it is an under-the-radar company that avoids traditional regulatory scrutiny given how it is incorporated. 7 Value Stocks That May Come Back into Style After the Pandemic Big yield, stock gains — another proven big dividend stock to be thankful for and to buy now. About Neil George: On the date of publication, Neil George did not hold (either directly or indirectly) any positions in the securities mentioned in this article.  As the editor of Profitable Investing, Neil George helps long-term investors achieve their growth & income goals with less risk. With 30+ years of experience in the financial markets, Neil recommends undiscovered and underappreciated companies that offer subscribers double-digit yields now and triple-digit returns over time.   More From InvestorPlace Why Everyone Is Investing in 5G All WRONG Top Stock Picker Reveals His Next 1,000% Winner Radical New Battery Could Dismantle Oil Markets The post 4 Big Dividends to Be Thankful For appeared first on InvestorPlace.
Wed, 18 Nov 2020 15:00:00 +0000	CloudBolt Announces $35 Million in Series B Funding Led by Insight Partners Investment enables CloudBolt with preeminent position in cost, security, and governance for the hybrid cloud, multi-tool automation marketNORTH BETHESDA, Md., Nov. 18, 2020 (GLOBE NEWSWIRE) -- CloudBolt Software, the enterprise leader in cloud management and integration solutions, today announced $35M in series B funding, consisting of both equity and venture debt. The equity was led by Insight Partners, a global venture capital and private equity firm. The venture debt is issued by Hercules Capital Inc. (NYSE: HTGC), widely recognized as the largest non-bank source of venture lending financing for technology, life sciences, and renewable energy companies, and Bridge Bank, a lender to industry-leading SMBs and emerging technology-focused ventures. “As enterprises accelerate their investments in hybrid cloud, they face growing challenges around shadow IT, lack of visibility, and complex integrations across their IT and DevOps toolsets,” said Jeff Kukowski, chief executive officer of CloudBolt Software. “These factors require a bold, new vision for cloud management where enterprises must continuously automate, secure, and optimize their cloud workloads while using their tools of choice. We are thrilled to have the support of Insight Partners, Hercules, and Bridge Bank as we build out our technology vision, accelerate our international expansion, and invest in new partnerships to support enterprises anywhere on their hybrid cloud, multi-tool journey.”According to Gartner, the cloud management platforms and tools (CMPT) market grew to over $1 billion in 2019 and is expected to grow at an estimated 20% compound annual growth rate (CAGR) through 2022. Over the past 12 months, CloudBolt has had banner success including doubling the size of its customer base, being named by Deloitte as one of the fastest growing technology companies in North America, and being ranked in the top 15% of all companies on the Inc. 5000 list. In addition, CloudBolt’s recent acquisitions of Kumolus and SovLabs have significantly strengthened the company’s hybrid cloud management vision.With the acquisitions, CloudBolt gains two powerful new capabilities: 1) a SaaS-based offering that enables enterprises to visualize their public cloud environments like AWS and Azure and continuously optimize them for cost, security, and compliance; and 2) a codeless integration platform, enabling IT to finally reduce the high cost and complexity of custom coding while providing better governance over their integration strategy across new and emerging toolsets like VMware vRealize Automation, HashiCorp Terraform, and more.“CloudBolt is growing impressively because of their long-term vision for hybrid cloud combined with their near-term execution success,” said Thomas Krane, Principal at Insight Partners. “As enterprises accelerate adoption of private and public cloud and new tools for their stack, the challenges around cost control, visibility, and governance intensify. CloudBolt’s strength in self-service IT—now married with deep cost management, security, and integration capabilities—position it as the key enabler for the enterprise hybrid cloud, multi-tool journey. We are excited to partner with Jeff and the rest of the executive team in taking CloudBolt to the next level of growth.”     “Hercules is proud to partner with CloudBolt and provide the financing required to advance the company’s product development efforts and expand its market footprint globally to achieve its impressive growth objectives,” said John Eggbeer, Managing Director at Hercules. “We’re impressed with the work that the CloudBolt executive team has already achieved and look forward to a great partnership with one of the market leading hybrid cloud software management companies.”“We are pleased to enter into a financing partnership with CloudBolt at this important stage of the company’s history to advance its product and go-to-market strategy,” said Mark Breneman, senior vice president in Bridge Bank’s Technology Banking Group. “We’re confident that CloudBolt’s management team will be able to seize on the rapidly growing hybrid cloud, multi-tool opportunity ahead of them.”About CloudBolt Software CloudBolt Software is the enterprise leader in cloud management and integration solutions. Our products are simple, so you achieve unrivaled time-to-value; our knowledge is deep, so you have a trusted cloud partner along your journey; our teams are obsessed with your success, so you become the enterprise IT hero. Today, CloudBolt’s award-winning cloud management platform and codeless integration solutions are deployed in enterprises worldwide for hybrid cloud. Backed by Insight Partners, CloudBolt Software is a Deloitte Fast 500 company, a CODiE award winner for cloud management, and featured in Gartner’s Magic Quadrant for Cloud Management Platforms. For more information, visit www.cloudbolt.io or follow us on Twitter @CloudBoltSW.About Insight Partners Insight Partners is a leading global venture capital and private equity firm investing in high-growth technology and software ScaleUp companies that are driving transformative change in their industries. Founded in 1995, Insight Partners has invested in more than 400 companies worldwide and has raised through a series of funds more than $30 billion in capital commitments. Insight's mission is to find, fund, and work successfully with visionary executives, providing them with practical, hands-on software expertise to foster long-term success. Across its people and its portfolio, Insight encourages a culture around a belief that ScaleUp companies and growth create opportunity for all. For more information on Insight and all its investments, visit insightpartners.com or follow us on Twitter @insightpartners.About Hercules Capital, Inc. Hercules Capital, Inc. (NYSE: HTGC) is the leading and largest specialty finance company focused on providing senior secured venture growth loans to high-growth, innovative venture capital-backed companies in a broad variety of technology, life sciences and sustainable and renewable technology industries. Since inception (December 2003), Hercules has committed more than $10.5 billion to over 500 companies and is the lender of choice for entrepreneurs and venture capital firms seeking growth capital financing. Companies interested in learning more about financing opportunities should contact info@htgc.com, or call (650) 289-3060.About Bridge Bank Bridge Bank, a division of Western Alliance Bank, Member FDIC, helps business clients realize their ambitions. Founded in 2001 in Silicon Valley, Bridge Bank offers a better way to bank for small-market and middle-market businesses across many industries, as well as emerging technology companies and the private equity community. Geared to serving both venture-backed and non-venture-backed companies, Bridge Bank delivers a broad scope of financial solutions including capital, equipment and working capital credit facilities, venture debt, treasury management, asset-based lending, SBA and commercial real estate loans, ESOP finance and a full line of international products and services. Based in San Jose, Bridge Bank has 16 offices in major markets across the country along with Western Alliance Bank’s powerful array of specialized financial services. Western Alliance Bank is the primary subsidiary of Phoenix-based Western Alliance Bancorporation. One of the country’s top-performing banking companies, Western Alliance has ranked in the top 10 on the Forbes “Best Banks in America” list for five consecutive years, 2016-2020, and was named 1 best-performing of the 50 largest public U.S. banks for 2019 by S&P Global Market Intelligence. For more information, visit bridgebank.com.
Wed, 04 Nov 2020 22:03:00 +0000	Hercules Capital Announces an Investment Grade Bond Offering Totaling $100.0 Million Due 2026 Hercules Capital, Inc. (NYSE: HTGC) ("Hercules" or the "Company") today announced a private offering totaling $100.0 million in aggregate principal amount of $50.0 million 4.50% Notes due March 2026 (the "November Notes") and $50.0 million 4.55% Notes due March 2026 (the "March Notes").
Tue, 03 Nov 2020 16:57:00 +0000	Udacity Drives 120% Enterprise and Government Growth in Q3, Secures $75 Million to Continue Momentum Udacity, which prepares employees and students for careers of the future, today announced its Q3 enterprise and government bookings rose by 120% year-over-year, total bookings increased 80% year-over-year, and ARR increased 260% in H1 2020. In addition, the company has reached profitability and, to continue building on this growth, Udacity has signed a $75 million debt facility, with Hercules Capital (NYSE: HTGC) serving as the underwriter.
Fri, 30 Oct 2020 16:13:04 +0000	Hercules Capital (HTGC) Q3 Earnings Beat, Revenues Rise Y/Y Hercules Capital (HTGC) records a rise in revenues and higher expenses in the third quarter of 2020.
Fri, 30 Oct 2020 10:01:36 +0000	Hercules Technology Growth Capital (HTGC) Q3 2020 Earnings Call Transcript Ladies and gentlemen, thank you for standing by, and welcome to the Hercules Capital third-quarter 2020 earnings conference call. Thank you, A.J. Good afternoon, everyone, and welcome to Hercules conference call for the third quarter of 2020. With us on the call today from Hercules are Scott Bluestein, CEO and chief investment officer; and Seth Meyer, CFO.
Thu, 29 Oct 2020 23:15:11 +0000	Hercules Technology (HTGC) Q3 Earnings and Revenues Surpass Estimates Hercules Tech (HTGC) delivered earnings and revenue surprises of 6.25% and 3.51%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Thu, 29 Oct 2020 20:10:00 +0000	Hercules Capital Reports Third Quarter 2020 Financial Results Hercules Capital, Inc. (NYSE: HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced its financial results for the third quarter ended September 30, 2020.
Thu, 29 Oct 2020 19:15:00 +0000	Hercules Capital, Inc. to Host Earnings Call NEW YORK, NY / ACCESSWIRE / October 29, 2020 / Hercules Capital, Inc.
Wed, 28 Oct 2020 20:10:00 +0000	Hercules Capital Gains Additional Liquidity for New Investments with Approval of Third SBA License Hercules Capital, Inc. (NYSE: HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced it received agency committee approval by the U.S. Small Business Administration (SBA) for a third Small Business Investment Company (SBIC) license. The SBIC license was issued following final action by the SBA Administrator. This additional license has a 10-year term and will provide up to $175 million of fixed-rate capital for investment.
Wed, 28 Oct 2020 14:36:02 +0000	Ares Capital (ARCC) Stock Gains 1.5% on Q3 Earnings Beat Ares Capital (ARCC) records a decline in total investment income in the third quarter of 2020.
Tue, 27 Oct 2020 10:02:00 +0000	Hercules Capital Announces Supplemental Cash Distribution of $0.02 per Share for the Third Quarter of 2020 Hercules Capital, Inc. (NYSE: HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, is pleased to announce that its Board of Directors has declared a supplemental cash distribution of $0.02 per share.
Tue, 27 Oct 2020 10:00:00 +0000	Hercules Capital Declares Cash Distribution of $0.32 per Share for the Third Quarter of 2020 Hercules Capital, Inc. (NYSE: HTGC) ("Hercules" or the "Company"), the largest and leading specialty finance provider to innovative, venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, is pleased to announce that its Board of Directors has declared a third quarter 2020 cash distribution of $0.32 per share. The following shows the key dates of the third quarter 2020 distribution payment:
Thu, 22 Oct 2020 10:00:00 +0000	Hercules Capital Announces Date for Release of Third Quarter 2020 Financial Results and Conference Call Hercules Capital, Inc. (NYSE: HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that it has scheduled its third quarter 2020 financial results conference call for Thursday, October 29, 2020, at 2:00 p.m. PT (5:00 p.m. ET). Hercules will release its financial results after market close that same day.
Thu, 01 Oct 2020 20:30:00 +0000	Geron Secures Loan Facility for Up to $75 Million Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it has entered into a loan facility for up to $75 million with Hercules Capital, Inc. (NYSE: HTGC) and Silicon Valley Bank (SVB). The loan facility provides the Company with access to non-dilutive financial resources to support the imetelstat development program, as well as working capital and general corporate purposes.
Tue, 29 Sep 2020 11:00:00 +0000	Axsome Therapeutics Announces $225 Million Term Loan Facility with Hercules Capital Non-dilutive committed capital extends cash runway into at least 2024 Facility strengthens balance sheet through anticipated commercial launches of Axsome’s two lead CNS product candidatesNEW YORK, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, has secured a $225 million term loan facility with Hercules Capital, Inc. (NYSE: HTGC). The committed capital strengthens the Company’s balance sheet through the anticipated commercial launches of its two lead product candidates, AXS-05 for major depressive disorder (MDD) and AXS-07 for migraine, and extends its cash runway into at least 2024, based on current operating plans.“The committed non-dilutive capital from this term loan facility increases our financial flexibility as we execute on the anticipated upcoming commercial launches of our first two potentially life-changing investigational medicines for patients living with depression and migraine,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome. “Simultaneously we will continue to advance the rest of our differentiated late-stage CNS pipeline which includes two other Breakthrough Therapy designated programs, AXS-05 in Alzheimer’s disease agitation and AXS-12 in narcolepsy, as we build a leading CNS company.”“Hercules is proud to partner with Axsome ahead of the filing of its New Drug Applications for AXS-05 in depression and for AXS-07 in migraine, and to support its work to develop novel treatments for the millions of patients with CNS disorders,” said Scott Bluestein, Chief Executive Officer and Chief Investment Officer of Hercules Capital. “The significant commitment from Hercules aligns with Axsome’s growth plans and provides an example of the breadth of our platform and our ability to finance life sciences companies through all stages of development.”Under the terms of the new $225 million term loan facility, $60 million may be drawn at closing; $115 million may be drawn at the Company’s option, in three separate tranches, upon approval of AXS-05 in MDD, upon approval of AXS-07 in migraine, and upon certain combined sales criteria for AXS-05 and AXS-07; and an additional $50 million is available, subject to the approval of Hercules Capital, to support future strategic initiatives, including further pipeline advancement or expansion. Of the initial $60 million, the Company drew down $50 million at closing, with the additional $10 million available to be drawn at the Company’s option. A portion of the initial drawdown was used to repay the Company’s previously existing $20 million principal loan with Silicon Valley Bank along with associated final payment fees. The new term loan facility bears interest at a calculated prime-based variable rate currently at 9.15%. It matures in October 2025 and has an initial interest-only payment period of 30 months, which may be extended to up to 48 months upon the drawing of future tranches. Axsome will issue warrants to purchase 15,541 shares of Axsome common stock upon initial funding of the facility.Additional details of the loan agreement, will be filed with the Securities and Exchange Commission on a Current Report on Form 8-K.About Axsome Therapeutics, Inc.Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For the many people facing unsatisfactory treatments for CNS disorders, Axsome accelerates the invention and adoption of life-changing medicines. Axsome’s core CNS product candidate portfolio includes five clinical-stage candidates, AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14. AXS-05 is being developed for major depressive disorder (MDD), treatment resistant depression (TRD), Alzheimer’s disease (AD) agitation, and as a treatment for smoking cessation. AXS-07 is being developed for the acute treatment of migraine. AXS-12 is being developed for the treatment of narcolepsy. AXS-14 is being developed for fibromyalgia. AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14 are investigational drug products not approved by the FDA. For more information, please visit the Company’s website at axsome.com. The Company may occasionally disseminate material, nonpublic information on the company website.About Hercules Capital, Inc.Hercules Capital, Inc. (NYSE: HTGC) is the leading and largest specialty finance company focused on providing senior secured venture growth loans to high-growth innovative venture capital-backed companies in a broad variety of technology, life sciences and sustainable and renewable technology industries. Since inception (December 2003), Hercules has committed more than $10.5 billion to over 500 companies and is the lender of choice for entrepreneurs and venture capital firms seeking growth capital financing.Forward Looking StatementsCertain matters discussed in this press release are “forward-looking statements”. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the success, timing and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of our ongoing clinical trials, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of our current product candidates; our ability to fund additional clinical trials to continue the advancement of our product candidates; the timing of and our ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, our product candidates (including, but not limited to, with or without a special protocol assessment); the potential for our clinical trials to provide a basis for accelerated approval of our product candidates for the treatment of several indications and accelerate their development timelines and commercial paths to patients (including, but not limited to, with or without a breakthrough therapy designation); the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s product candidates, if approved; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and our ability to fund our commercial launch, which assumes product approval; unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19; and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance.Axsome Contact: Mark Jacobson Chief Operating Officer Axsome Therapeutics, Inc. 22 Cortlandt Street, 16th Floor New York, NY 10007 Tel: 212-332-3243 Email: mjacobson@axsome.com www.axsome.com
Tue, 01 Sep 2020 15:29:48 +0000	Hercules Capital (NYSE:HTGC) Share Prices Have Dropped 14% In The Last Year Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. When you...
Sat, 29 Aug 2020 15:31:03 +0000	Why Is Hercules Tech (HTGC) Up 1.7% Since Last Earnings Report? Hercules Tech (HTGC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Tue, 04 Aug 2020 13:55:48 +0000	3 “Strong Buy” Dividend Stocks That Pay Over 9% You can’t always rely on share price appreciation to guarantee a profitable portfolio. Savvy investors know this, and always seek ways to ensure their income stream. Dividends are a common, and popular, way to do this, but bring with them some important questions: Is the dividend reliable – does the company pay it out regularly, in full? Does it yield enough to make the investment worthwhile?These are some of the factors that Wall Street’s analysts weigh when they review dividend stocks. And fortunately, they can answer them in positive terms for investors. While the market conditions aren’t really signaling defensive buying – the S&P 500 has been holding above 3,200 since mid-July, and the NASDAQ has been setting new record highs since June – keeping a reserve of defensive stocks is always a sound strategy to harden your portfolio against the unexpected.With this in mind, we’ve turned to TipRanks database to find three "Strong Buy" dividend stocks with yields starting at 9%, high by any standard, and with potential upsides starting at 14%. These are stocks that will both grow the portfolio and provide a steady income.Hercules Capital (HTGC)We’ll start in venture capital, the engine of so much economic activity. Hercules Capital offers financing services to small, early-stage companies in the technology, life sciences, and financial SaaS sectors, and boasts some $10 billion committed to its investment portfolio.HTGC weathered the corona storm well in the first quarter, reporting strong EPS above the estimates. Q2, however, saw a decline. Investment income fell nearly 2% year-over-year, and EPS dropped to 32 cents, missing the forecast by one cent. Hercules saw a boost from a 5% drop in operating expenses.The quarterly results, while disappointing, were enough to ensure the company’s generous dividend. Hercules has a history of adjusting the payment to keep it line with earnings, but this quarter’s 32 cents per common share was kept stable. The annualized rate, $1.28, gives a yield of nearly 11.1%, which is far better than the 2% average yield found among S&P-listed companies. Hercules has a 13-year history of keeping reliable dividend payments.Tim Hayes, of B. Riley FBR, writes of Hercules, “While lower interest rates weighed on earnings power during the quarter, NII/share covered the $0.32/share quarterly dividend, and we expect the dividend to remain stable in the near-/intermediate term given the healthy cash runway amongst portfolio companies and a strong VC backdrop [...] we remain buyers of shares of HTGC, which currently trade at 1.08x 2Q20 NAV."In line with these comments, Hayes rates HTGC a Buy along with a $12.50 price target, which implies a 9% upside from current levels. (To watch Hayes’ track record, click here)Wall Street clearly agrees with Hayes – Hercules has a unanimous Strong Buy analyst consensus rating, based on 9 analyst reviews. The stock is selling for $11.45 and the average price target of $12.57 is in congruent with Hayes’, suggesting a one-year upside of 10%. (See HTGC stock analysis on TipRanks)Global Net Lease (GNL)Next up, Global Net Lease, is a real estate investment trust. REITs are typically dividend champs, due to tax code provisions requiring them to return a high percentage of earnings directly to investors. GNL, with a portfolio built on US and European commercial properties, aims to provide investors with stable dividends and steady portfolio growth potential. While the growth potential has stalled in recent months, due to the ongoing coronavirus crisis, the company’s stock shares are up 94% since hitting bottom in March. Earnings during 1H20, the ‘corona half,’ have been stable, at 44 cents per share for Q1.In an effort to keep the dividend and EPS in line together, the company cut back the quarterly dividend payment during the half. The current dividend is 40 cents per share, making the yield 9.6%. This is impressive on its own, but more so considering that it comes after a 20% cut and while the stock has been gradually gaining ground.Berenberg analyst Nathan Crossett writes, “The strength of GNL’s portfolio through diversification and focus on investment grade tenancy is exemplified by the level of its rent collections during the peak of the pandemic. As of June 2, GNL had collected 96% of the original cash rent due quarter to date for the second quarter; this includes 99% of rent for assets in the United Kingdom and 97% of rent for assets in the rest of Europe.”A REIT with that level of success in rent collection is easily rated a Buy, and Crossett adds a $22 price target, suggesting room for 34% upside growth. (To watch Crossett’s track record, click here)Overall, Global Net Lease has 3 Buys and 1 Hold behind its Strong Buy consensus rating. The stock is selling for $16.43 and has an average price target of $20.17, giving it a 23% upside potential. (See GNL stock analysis on TipRanks)Cherry Hill Mortgage (CHMI)Last on today’s list is Cherry Hill Mortgage, named for its headquarters town in New Jersey. This REIT holds a portfolio of mortgage-based assets rather than direct property ownership. CHMI’s portfolio includes heavy investments in mortgage service rights and mortgage-backed securities.Through the first quarter, Cherry Hill beat the forecasts on earnings. Quarterly EPS in both Q4 and Q1 were from Q3 2019, an impressive feat during a period when most companies were seeing sharp drops sequentially. Q1 EPS came in at 47 cents, compared to a 43-cent expectation.In a nod to the ongoing health and financial crises, CHMI cut back on its dividend payment in Q2. The company set the payment at 27 cents per share of common stock, giving an annualized payment of $1.08 and a yield of 11.7%. That dividend yield compares favorably to most other investments, especially US Treasury bonds which are currently at record low rates.5-star analyst Steven DeLaney, of JMP Securities, likes what he sees in CHMI, viewing the company as fundamentally sound. He writes, “in the wake of the March-April market disruption and 1Q20 results … core earnings and book value held up relatively well despite unprecedented COVID-19-related market volatility. We continue to view the company’s valuation as attractive…”DeLaney’s $10.50 price target supports his Buy rating and suggests a solid one-year upside for the stock of 15.5%. (To watch DeLaney’s track record, click here)Cherry Hill is another company with a unanimous Strong Buy analyst consensus rating, this one based on 3 recent reviews. The stock’s average price target of $11.33 is somewhat more bullish than DeLaney allows, indicating room for a 25% upside in the next 12 months. (See Cherry Hill’s stock analysis at TipRanks)To find good ideas for divided stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

If you are already a Value Forum member but are not logged on, click here to log on. If you are a guest, thank you for visiting ValueForum -- click here for information about guest access or click here to join -- a Trial Pass can be purchased for $6.99 to help you decide if you want to commit to longer term membership. Did you know there are customized portals into VF like BDCs.ValueForum.com and also My ValueForum which lets you customize your VF experience to the posters and topics that most interest you!